Status:
COMPLETED
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Locally Advanced or Metastatic Breast Cancer
Eligibility:
All Genders
Brief Summary
The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of locally advanced or metastatic breast cancer
- Participants who were treated with Eribulin between 01 June, 2014 and 31 December, 2016
Exclusion
- Not applicable
Key Trial Info
Start Date :
January 25 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT03437083
Start Date
January 25 2018
End Date
June 30 2018
Last Update
January 25 2019
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Eisai Trial site_03
Ansan, South Korea
2
Eisai Trial site_04
Busan, South Korea
3
Eisai Trial site_05
Busan, South Korea
4
Eisai Trial site_06
Busan, South Korea